Madhav Desai

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
    M Kay Garcia
    Department of Lymphoma Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0429, Houston, Texas 77030, USA
    J Hematol Oncol 7:41. 2014
  2. doi request reprint Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
    M Wang
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Leukemia 27:1902-9. 2013
  3. ncbi request reprint Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
    Michael L Wang
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 369:507-16. 2013
  4. doi request reprint Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
    Michael Wang
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 13:716-23. 2012
  5. doi request reprint Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
    Michael Wang
    Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:4445-51. 2008
  6. ncbi request reprint Use of bortezomib in B-cell non-Hodgkin's lymphoma
    Michael Wang
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, TX 77030 4009, USA
    Expert Rev Anticancer Ther 6:983-91. 2006
  7. doi request reprint Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:200-8. 2010
  8. doi request reprint Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma
    Michael Wang
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 113:2734-41. 2008
  9. doi request reprint Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd 429, Houston, TX 77030, USA
    Br J Haematol 151:47-53. 2010
  10. pmc Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Am J Hematol 87:272-6. 2012

Detail Information

Publications72

  1. pmc Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
    M Kay Garcia
    Department of Lymphoma Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0429, Houston, Texas 77030, USA
    J Hematol Oncol 7:41. 2014
    ..This single-arm study evaluated feasibility, safety, and initial efficacy of electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy (PN) in cancer patients with multiple myeloma...
  2. doi request reprint Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
    M Wang
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Leukemia 27:1902-9. 2013
    ..9 months. Rituximab plus oral lenalidomide is well tolerated and effective for patients with relapsed/refractory DLBCL and TL. SCT after lenalidomide-rituximab is associated with prolonged response duration. ..
  3. ncbi request reprint Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
    Michael L Wang
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 369:507-16. 2013
    ..In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma...
  4. doi request reprint Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
    Michael Wang
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 13:716-23. 2012
    ....
  5. doi request reprint Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
    Michael Wang
    Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:4445-51. 2008
    ..Studies were registered at http://www.clinicaltrials.gov under NCT00056160 and NCT00424047...
  6. ncbi request reprint Use of bortezomib in B-cell non-Hodgkin's lymphoma
    Michael Wang
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, TX 77030 4009, USA
    Expert Rev Anticancer Ther 6:983-91. 2006
    ..Mantle cell lymphoma was significantly more sensitive to bortezomib than other non-Hodgkin's lymphomas. Bortezomib may have far-reaching potential in the treatment of B-cell non-Hodgkin's lymphoma...
  7. doi request reprint Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:200-8. 2010
    ..We conclude that intense chemoimmunotherapy without stem cell transplantation is effective for untreated aggressive MCL...
  8. doi request reprint Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma
    Michael Wang
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 113:2734-41. 2008
    ....
  9. doi request reprint Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd 429, Houston, TX 77030, USA
    Br J Haematol 151:47-53. 2010
    ..In particular, there was no pulmonary or neurological dose-limiting toxicity, showing that bortezomib can be safely combined with R-HyperCVAD and R-M/A...
  10. pmc Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Am J Hematol 87:272-6. 2012
    ..Further studies should be conducted in carefully designed clinical trials in this patient population...
  11. pmc Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
    Deborah J Kuhn
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
    Blood 120:3260-70. 2012
    ....
  12. pmc Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis
    Yuhuan Zheng
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:3625-8. 2009
    ..Thus, our results indicate that Mvarphis may contribute to myeloma cell survival and resistance to chemotherapeutic treatment in vivo...
  13. pmc Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities
    Hyun Joo Jung
    Centre for Stem Cell Research, Brown Foundation Institute of Molecular Medicine for Prevention of Human Diseases, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Blood 119:2568-78. 2012
    ..TG2 inhibition may be used as an alternative target anti-MCL therapy, and calcium blockers may be combined with bortezomib to overcome the bortezomib resistance in MCL...
  14. pmc Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma
    Jianfei Qian
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:3880-9. 2009
    ....
  15. ncbi request reprint Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma
    Andre Goy
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 459, Houston, TX 77030, USA
    J Clin Oncol 23:667-75. 2005
    ..Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma...
  16. doi request reprint Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma
    Weijun Fu
    Department of Lymphoma Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Oncol 35:562-5. 2012
    ..Combinations of bortezomib, cyclophosphamide, and dexamethasone are rational with the prospect of superior antitumor activity with independent toxicity...
  17. doi request reprint Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study
    Haijun Wang
    Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Cancer 118:3793-800. 2012
    ..Waldenstrom macroglobulinemia (WM) is a non-Hodgkin lymphoma (NHL) subtype. Little is known about the incidence and trends for this disease in the United States...
  18. doi request reprint Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo
    Luhong Sun
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Res 36:363-8. 2012
    ..Our results demonstrate that ATI and BTZ confer significant therapeutic effects in MCL in vitro and in vivo and should therefore be investigated in a clinical trial in patients with relapsed or refractory MCL...
  19. ncbi request reprint High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
    Jorge E Romaguera
    Department of Lymphoma, Unit 429, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:7013-23. 2005
    ..To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL)...
  20. doi request reprint Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial
    Muzaffar H Qazilbash
    Department of Stem Cell Transplantation and Cellular Therapy, UT M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:1401-7. 2008
    ..Addition of ATO + AA to high-dose melphalan is safe and well tolerated as a preparative regimen for MM...
  21. doi request reprint Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma
    Uday Popat
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 15:718-23. 2009
    ..In patients with multiple myeloma, prior lenalidomide therapy is associated with failure of stem cell mobilization with filgrastim. Remobilization with chemotherapy and filgrastim is usually successful in these patients...
  22. pmc Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide
    Chad C Bjorklund
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 286:11009-20. 2011
    ....
  23. doi request reprint Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo
    Zhengzi Qian
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Leuk Res 35:380-6. 2011
    ..Importantly, the combination of LEN and DEX delayed the tumor growth and improved the survival of MCL-bearing mice. The results support the use of the LEN and DEX combination as a new therapeutic regimen in clinical trials of MCL...
  24. ncbi request reprint Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis
    Jing Yang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 12:252-65. 2007
    ..CRP also enhanced myeloma cell secretion of IL-6 and synergized with IL-6 to protect myeloma cells from chemotherapy drug-induced apoptosis. Thus, our results implicate CRP as a potential target for cancer treatment...
  25. doi request reprint A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma
    Michael Wang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:2154-60. 2008
    ..To establish a severe combined immunodeficient (SCID)-hu in vivo mouse model of human primary mantle cell lymphoma (MCL) for the study of the biology and novel therapy of human MCL...
  26. doi request reprint Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
    Liang Zhang
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Am J Hematol 84:553-9. 2009
    ....
  27. ncbi request reprint Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
    Donna M Weber
    Department of Lymphoma and Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 357:2133-42. 2007
    ..Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma...
  28. pmc Targeting cell surface β2 -microglobulin by pentameric IgM antibodies
    Yabing Cao
    Department of Lymphoma Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 154:111-21. 2011
    ..Thus, we developed and validated the efficacy of anti-β(2) M IgM mAbs that may be utilized in the clinical setting and showed that IgM anti-β(2) M mAbs may be more potent than IgG mAbs at inducing tumour apoptosis...
  29. pmc Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts
    Jing Yang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:3028-35. 2007
    ..Thus, this study further defines the tumoricidal mechanism of the mAbs and provides strong evidence to support the potential of these mAbs as therapeutic agents for myeloma...
  30. pmc Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells
    Liang Zhang
    Department of Lymphoma Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:3783-92. 2012
    ..Hence, our study identifies IL-6 as a key cytokine for MCL growth and survival and suggests that targeting the IL-6 pathway may be a novel way to improve the efficacy of chemotherapy in MCL patients...
  31. doi request reprint Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma
    Michael Wang
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:5213-8. 2009
    ..This phase II trial evaluated the safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma (MCL)...
  32. ncbi request reprint Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 53:118-22. 2012
    ..These results indicate that high-dose melphalan plus auto HCT is safe and feasible for patients with multiple myeloma aged ≥70 years and age alone should not be an exclusion criterion for auto HCT...
  33. ncbi request reprint Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Eur J Cancer 42:2976-81. 2006
    ..Pegfilgrastim was found to be safe in support of ABVD chemotherapy that is administered every 14 d. Pegfilgrastim was also effective in maintaining ABVD dose intensity, and keeping planned dose of chemotherapy on schedule...
  34. pmc HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma
    Richard J Jones
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 118:4140-9. 2011
    ..These findings provide a framework for translation of the rational combination of an HDM-2 and RNR inhibitor to the clinic for patients with relapsed wtp53 MCL...
  35. doi request reprint Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma
    Gaurav C Parikh
    Department of Stem Cell Transplantation and Cellular Therapy, M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 15:812-6. 2009
    ..In this analysis, a melphalan (Mel) dose of 200 mg/m(2) was not associated with an increase in toxicity or nonrelapse (Mel) mortality (NRM)...
  36. doi request reprint Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma
    Michael Wang
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:3231-41. 2008
    ..There is a lack of research on ethnic disparities in survival among patients with non-Hodgkin lymphoma (NHL), although these disparities have been documented for patients with many other tumors...
  37. ncbi request reprint Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma
    Michael Wang
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Am J Hematol 79:194-7. 2005
    ..Thalidomide-dexamethasone was useful for these patients with advanced disease because of the high response rate and acceptable survival, with a low frequency of serious complications...
  38. pmc Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma
    Hyun Joo Jung
    Centre for Stem Cell Research, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Exp Hematol 40:107-18.e2. 2012
    ..Given that the NF-κB expression in MCL-ICs is resistant to bortezomib, it will be important to find alternative therapeutic strategies to inhibit NF-κB expression...
  39. ncbi request reprint Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways
    Michael Wang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 109:5455-62. 2007
    ..Cell apoptosis was induced mainly via activation of the AIF pathway. These results support the use of atiprimod as a potential agent in MCL chemotherapy...
  40. pmc Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma
    Jianfei Qian
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:1587-94. 2007
    ..Hence, our study identifies DKK1 as a potentially important antigen for immunotherapy in MM...
  41. ncbi request reprint Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma
    Nam H Dang
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    J Clin Oncol 22:4095-102. 2004
    ..A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL...
  42. pmc Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
    Sally A Hunsucker
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Br J Haematol 152:579-92. 2011
    ..These studies provide a rationale for translation of siltuximab into the clinic in combination with melphalan-based therapies...
  43. doi request reprint Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004
    Yuhong Zhou
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:791-8. 2008
    ..The purpose of the current study was to examine the incidence of MCL over a period of 13 years and to identify the factors associated with the incidence patterns...
  44. ncbi request reprint Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma
    Amar Safdar
    Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Infect Dis 194:1394-7. 2006
    ..For each vaccine, the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135- microg vaccine...
  45. ncbi request reprint Chemotherapy and survival for patients with multiple myeloma: findings from a large nationwide and population-based cohort
    Nidhi Rohatgi
    Division of Epidemiology, School of Public Health, University of Texas Health Science Center, Houston, TX 77030, USA
    Am J Clin Oncol 30:540-8. 2007
    ..To assess the patterns of chemotherapy use for patients with multiple myeloma and to determine if chemotherapy is effective in prolonging survival outside the clinical trial settings...
  46. pmc Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes
    Jinsheng Weng
    Department of Lymphoma and Myeloma, Stem Cell Transplantation and Cellular Therapy, and Center for Cancer Immunology Research, MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 17:5945-52. 2011
    ..However, epitopes derived from Id that stimulate human CD8(+) T-cell immunity are incompletely characterized...
  47. pmc Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma
    Yvonne A Efebera
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Biol Blood Marrow Transplant 16:1122-9. 2010
    ..The use of RIC allo-HSCT earlier in the course of the disease may offer the greatest benefit...
  48. ncbi request reprint Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma
    Raymond Alexanian
    The University of Texas M D Anderson Cancer Center, Box 429, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Semin Hematol 40:3-7. 2003
    ..Our program of thalidomide/dexamethasone was a safe and effective combination for patients with resistant or relapsing disease, or as consolidation of partial remission after intensive therapy...
  49. pmc Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
    Madhav Desai
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Hematol Oncol 6:55. 2013
    ..This review will serve as a tool guiding future clinical investigations to improve survival rates for these three lymphomas. ..
  50. pmc Prospective isolation of clonogenic mantle cell lymphoma-initiating cells
    Zheng Chen
    Centre for Stem Cell Research, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases IMM, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Stem Cell Res 5:212-25. 2010
    ....
  51. doi request reprint Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo
    Jianguo Wen
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, 6565 Fannin MS205, Houston, TX 77030, USA
    Mol Cancer Ther 10:148-58. 2011
    ..Our findings indicate that Cetrorelix induces cytotoxicity in myeloma cells through various mechanisms and provide a rationale for investigating Cetrorelix for the treatment of MM...
  52. ncbi request reprint International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
    S Giralt
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Leukemia 23:1904-12. 2009
    ..The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions...
  53. pmc Effect of long-term storage in TRIzol on microarray-based gene expression profiling
    Wencai Ma
    The Myeloma Tissue and Leukemia Satellite Sample Banks, Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, Texas 77054, USA
    Cancer Epidemiol Biomarkers Prev 19:2445-52. 2010
    ....
  54. ncbi request reprint Dominant negative signal transducer and activator of transcription 2 (STAT2) protein: stable expression blocks interferon alpha action in skin squamous cell carcinoma cells
    John L Clifford
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 2:453-9. 2003
    ..Furthermore, we propose that these dnSTAT2-expressing cells provide a novel in vitro model for the study of type I IFN action in human skin cells...
  55. pmc Curability of multiple myeloma
    Raymond Alexanian
    University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Bone Marrow Res 2012:916479. 2012
    ..In addition to immunofixation, more sensitive techniques for the detection of residual disease should be applied more consistently in patients with apparent complete remission in order to identify those with potential cure...
  56. ncbi request reprint Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia
    Ellen C Mullen
    University of Texas M D Anderson Cancer Center, Houston, USA
    Clin J Oncol Nurs 11:87-95. 2007
    ..Although hyperviscosity syndrome is not one of the most common conditions, when it does occur, oncology nurses play a critical role in patients' assessment and care...
  57. ncbi request reprint Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant
    Muzaffar H Qazilbash
    Stem Cell Transplantation and Cellular Therapy, UT M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:1066-72. 2007
    ..02 and .08, respectively). Deletion 1p is associated with a significantly shorter remission and survival in patients undergoing high-dose therapy and a single autologous transplant for myeloma...
  58. doi request reprint High frequencies of response after limited primary therapy for multiple myeloma
    Raymond Alexanian
    Department of Lymphoma Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Clin Lymphoma Myeloma Leuk 13:119-22. 2013
    ..Remissions occurred in approximately 90% of patients, with rare episodes of serious drug-related adverse effects...
  59. doi request reprint Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma
    Kejie Zhang
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Exp Hematol 41:67-78.e4. 2013
    ..Our data suggest that SINE CRM1 antagonists are a potential novel therapy for patients with MCL, particular in relapsed/refractory disease...
  60. ncbi request reprint Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies
    Jing Yang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Cell 10:295-307. 2006
    ..Therefore, such mAbs offer the potential for a therapeutic approach to hematological malignancies...
  61. pmc Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells
    Xiaoying Liu
    Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Biochem Pharmacol 83:1456-64. 2012
    ..Our results indicate that NSC-743380 is a potent anticancer agent for lung cancer and that its apoptotic effects in lung cancer cells are mediated by induction of ROS through STAT3 inhibition...
  62. doi request reprint Outcomes in lymphoma patients with obstructive jaundice: a cancer center experience
    William A Ross
    Department of Gastroenterology, Hepatology and Nutrition, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Dig Dis Sci 55:3271-7. 2010
    ..Little information is available to guide clinicians on the optimal approach to managing obstructive jaundice in lymphoma patients...
  63. ncbi request reprint Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases
    Martin Majer
    Multidisciplinary Melanoma Program, Huntsman Cancer Institute, Salt Lake City, Utah, USA
    Cancer 110:1329-37. 2007
    ....
  64. ncbi request reprint A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings
    Edward A Stadtmauer
    Hematology Oncology Division, University of Pennsylvania Health System, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Clin Adv Hematol Oncol 5:7-19, quiz 21-2. 2007
  65. ncbi request reprint Current status and future directions in the treatment of multiple myeloma
    Jian Hou
    Chin Med J (Engl) 120:1651-4. 2007
  66. ncbi request reprint Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond
    Yuhong Zhou
    Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
    Am J Hematol 83:144-9. 2008
    ..A Phase I/II study is ongoing to determine the maximum tolerated dose (MTD) and the efficacy of lenalidomide in combination with Rituximab for relapsed/refractory MCL. This review summarizes the latest and exciting advances in MCL...
  67. ncbi request reprint Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
    Nam H Dang
    Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Br J Haematol 138:502-5. 2007
    ..The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon...
  68. ncbi request reprint Bim and Bcl-2 mutually affect the expression of the other in T cells
    Trine N Jorgensen
    Integrated Department of Immunology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Immunol 179:3417-24. 2007
    ..These mutual effects occur even if Bcl-2 is induced acutely. Thus these two proteins control the expression of the other, at either the protein or mRNA level...
  69. ncbi request reprint Influence of physicochemical properties and intestinal region on the absorption of 3-fluoro-2-pyrimidylmethyl 3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide, a water insoluble thrombin inhibitor, in dogs
    Danielle Euler
    Department of Pharmaceutical Research and Development, Merck and Co, Inc, West Point, PA 19486, USA
    Int J Pharm 275:19-27. 2004
    ..Regional absorption results suggested that the compound was absorbed along the gastrointestinal tract in Beagle dogs, however colonic absorption appeared to be reduced by slower dissolution...
  70. ncbi request reprint Modulation of immune system function by measles virus infection. II. Infection of B cells leads to the production of a soluble factor that arrests uninfected B cells in G0/G1
    Michael Wang
    Division of Hematology Oncology Bone Marrow Transplantation, The Children s Hospital Denver, Colorado, USA
    Viral Immunol 16:45-55. 2003
    ....
  71. doi request reprint The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement
    M A Hussein
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Leukemia 22:1479-84. 2008
  72. ncbi request reprint Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS)
    Wolfram E Samlowski
    Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA
    Cancer 109:1855-62. 2007
    ..We performed a retrospective analysis of our institutional experience of multimodality treatment utilizing linear accelerator (Linac)-based stereotactic radiosurgery (SRS)...